Abstract
Editorial: "How to Improve Cord Blood Transplantation: By Enhancing Cell Counts or Engraftment?".
Highlights
Stem cell content of CB was known for a long time the first and successful human cord blood transplantation (CBT) was made possible in 1988
The initial experience began with CBTs from human leukocyte antigen (HLA)-matched sibling CB, later unrelated CB has become the major source (Beksac)
In this mini-review, there is a chapter written by the group led by Shpall, MD Anderson Cancer Center. They will discuss their pioneering experience of expanding CB cells with mesenchymal progenitor cells (Mehta et al.) and other methods such as use of HPC-differentiation blockers, i.e., nicotinamide analogs, copper chelators, inducing constitutive Notch signaling, or an aryl hydrocarbon receptor antagonist (StemReginin1). Many of these methods lead to substantial expansions of CD34+ cells, and significantly improving time to engraftment in patients transplanted with the expanded products compared to the recipients of unmanipulated CBT
Summary
Department of Hematology and Cord Blood Bank, Ankara University, Ankara, Turkey Keywords: cord blood transplantation, engraftment, expansion, cellular therapy, natural killer cells The Editorial on the Research Topic How to Improve Cord Blood Transplantation: By Enhancing Cell Counts or Engraftment? Specialty section: This article was submitted to Hematology, a section of the journal
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call